Rehabilitation Plan Approval Improves Financial Structure, Uncertainty Remains


  • Rehabilitation plan approved by Suwon Bankruptcy Court on March 20, 2026
  • Debt-to-equity swap of 22,479 million won at 100 won per share, 6:1 stock consolidation, and issuance of 165 million new shares via third-party allocation
  • Resolved capital impairment: consolidated equity from -22,525 million won to +23,828 million won
  • Change in largest shareholder to Haemily Co., Ltd. (48.77%)
  • Continued operating loss: consolidated operating loss of 1,300 million won in Q1 2026
  • Recorded net profit of 24,689 million won due to debt forgiveness gain of 26,018 million won
  • Ongoing litigation regarding delisting (injunction, etc.)
  • Material uncertainty related to going concern
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: Eone Diagnomics Genome Center (245620)
  • Submission: Eone Diagnomics Genome Center Co., Ltd.
  • Receipt: 05-15-2026